NCT01612351 2026-03-17
Multimodality Risk Adapted Tx Including Induction Chemo for SCCHN Amenable to Transoral Surgery
UNC Lineberger Comprehensive Cancer Center
Phase 2 Completed
Clinical Trials
7 trialsNCT07209189 2026-03-09
(NeoScorch HN)
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Recruiting
NCT05681039 2026-03-02
Phase 2 Trial of Neoadjuvant and Adjuvant Tiragolumab Plus Atezolizumab in Patients With Newly Diagnosed PD-L1 CPS Positive Resectable Stage 3-4 Oral Cavity Squamous Cell Carcinoma (OCSCC).
M.D. Anderson Cancer Center
Phase 2 Recruiting
NCT03174275 2026-02-23
Carboplatin, Nab-Paclitaxel, Durvalumab Before Surgery and Adjuvant Therapy in Head and Neck Squamous Cell Carcinoma
UNC Lineberger Comprehensive Cancer Center
Phase 2 Active not recruiting
NCT07214987 2026-01-30
PDT For Induction Therapy For Head And Neck Cancer
Massachusetts General Hospital
Phase 2 Not yet recruiting
NCT05366166 2026-01-28
Pembrolizumab Plus Olaparib in LA-HNSCC
UNC Lineberger Comprehensive Cancer Center
Phase 2 Active not recruiting
NCT06236425 2026-01-08
TBio-4101 and Pembro wi/ or w/o Chemo in Recurrent/Metastatic HNSCC
H. Lee Moffitt Cancer Center and Research Institute
Phase 1 Active not recruiting